Acorda Therapeutics Company Profile

18:31 EDT 19th September 2017 | BioPortfolio

Acorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial development efforts on a range of therapeutics for individuals with chronic, or long term, SCI. Currently, there is no therapy that improves neurological function in chronic SCI patients.

However, Acorda's clinical stage product, Fampridine-SR, has improved neurological function for patients with chronic SCI in Phase 2 clinical trials. The Company believes that the therapeutic products it develops for SCI are likely also to have applications in other neurological conditions-for example, both Fampridine-SR and the Company's M1 monoclonal antibody ("M1") product have shown promise as therapies for multiple sclerosis ("MS"). Other potential markets for the Company's products include traumatic brain injury, Parkinson's disease and stroke.


15 Skyline Drive
United States of America


Phone: 914-347-4300
Fax: 914-347-4560

News Articles [1577 Associated News Articles listed on BioPortfolio]

FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble

The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is cri...

Parkinson’s drug setback hits Acorda stock hard

More than 24% was taken off the market value of neurological disorders specialist Acorda Therapeutics…

Inbrija NDA to be filed by Acorda

Acorda Therapeutics will submit to the FDA its new-drug application for Inbrija by the end of this quarter. -More- 

US FDA says Acorda can't file Inbrija NDA and asks for production data

The US FDA has refused to let Acorda Therapeutics Inc. file Inbrija, its inhalable version of levodopa, for review.

STAT Plus: Acorda suffers embarrassing, costly delay to FDA review of Parkinson’s drug

Acorda Therapeutics was turned away at the FDA’s doorstep when it tried to submit a marketing application for a new drug to treat Parkinson’s disease.

Acorda Submits New Drug Application to U.S. Food and Drug Administration for Inbrija (CVT-301, Levodopa Inhalation Powder)

ARDSLEY, N.Y.--(BUSINESS WIRE) June 29, 2017 -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Inbrija (CVT-301,...

FDA Refuses to File Acorda NDA for Inbrija

Acorda Therapeutics said today it will work to address FDA concerns that prompted the agency to send a “Refuse to File” (RTF) letter in response to the company’s New Drug Application (NDA) for P...

Acorda adopts poison pill provision in response to recent accumulation of stock

Aimed at fending off a potential hostile bid for the company, Acorda Therapeutics adopts a poison pill provision effective today declaring a dividend distribution of one preferred share purchase right...

Clinical Trials [116 Associated Clinical Trials listed on BioPortfolio]

Open-Label Extension Study

The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an ...

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in subjects who previously participated in ...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [1145 Associated Companies listed on BioPortfolio]

Acorda Therapeutics

Acorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial develo...

Acorda Therapeutics, Inc.

Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and other nervous system disorders. The Company's marketed products ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Acorda Therapeutics" on BioPortfolio

We have published hundreds of Acorda Therapeutics news stories on BioPortfolio along with dozens of Acorda Therapeutics Clinical Trials and PubMed Articles about Acorda Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acorda Therapeutics Companies in our database. You can also find out about relevant Acorda Therapeutics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...

Corporate Database Quicklinks

Searches Linking to this Company Record